MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-10-2026
ICON Public Limited Company Interest Expense 2011-2026 | ICLR
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 337 M | 230 M | 182 M | 13 M | 13.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 337 M | 13 M | 155 M |
Quarterly Interest Expense ICON Public Limited Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 44.4 M | - | - | - | 2.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44.4 M | 2.73 M | 23.6 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.11 | -2.51 % | $ 101 K |  USA |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.45 | -3.67 % | $ 1.84 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 30.5 | -4.72 % | $ 328 M |  China |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Castle Biosciences
CSTL
|
1 K | $ 40.78 | 1.92 % | $ 1.13 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | - | - | $ 79.8 M | USA |
 |
DexCom
DXCM
|
20.3 M | $ 70.44 | 1.29 % | $ 27.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 113.62 | 1.32 % | $ 13.9 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 147.36 | 4.03 % | $ 23.4 B | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 20.08 | 0.35 % | $ 1.08 B | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 234.95 | -0.44 % | $ 172 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 105.63 | -1.25 % | $ 4.17 B | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 12.48 | 0.28 % | $ 354 M | Israel |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 27.65 | -1.53 % | $ 836 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 102.21 | -0.22 % | $ 18.9 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 66.02 | 2.75 % | $ 4.57 B | USA |
 |
Medpace Holdings
MEDP
|
4.06 M | $ 602.32 | -1.41 % | $ 18.6 B | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 234.18 | -1.47 % | $ 42.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.28 | 0.27 % | $ 2.01 B | USA |
 |
National Research Corporation
NRC
|
862 K | $ 22.06 | -0.72 % | $ 541 M | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 219.04 | -0.3 % | $ 11.3 B | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.3 | 1.56 % | $ 902 M | USA |
 |
Pacific Biosciences of California
PACB
|
14.3 M | $ 2.36 | 6.79 % | $ 599 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 188.87 | -0.33 % | $ 21 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 8.85 | 12.25 % | $ 1.15 B | USA |
 |
Mettler-Toledo International
MTD
|
74.6 M | $ 1 409.56 | -3.5 % | $ 29.9 B |  Schweiz |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 272.02 | 0.42 % | $ 22.8 B | USA |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 688.67 | -3.73 % | $ 56.8 B | USA |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 5.65 | -4.56 % | $ 512 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.67 | -2.3 % | $ 2.51 M | USA |
 |
Agilent Technologies
A
|
81 M | $ 135.52 | -2.95 % | $ 41.2 B | USA |